Molnupiravir-d7
Product Specifications
UNSPSC Description
Molnupiravir-d7 is the deuterium labeled Molnupiravir. Molnupiravir (EIDD-2801) is an orally bioavailable prodrug of the ribonucleoside analog EIDD-1931. Molnupiravir has broad spectrum antiviral activity against influenza virus and multiple coronaviruses, such as SARS-CoV-2, MERS-CoV, SARS-CoV. Molnupiravir has the potential for the research of COVID-19, and seasonal and pandemic influenza[1][2].
Target Antigen
Influenza Virus; SARS-CoV
Type
Isotope-Labeled Compounds
Related Pathways
Anti-infection
Field of Research
Inflammation/Immunology
Smiles
O=C(N([C@@]1([H])[C@H](O)[C@H](O)[C@@]([H])(COC(C(C([2H])([2H])[2H])([2H])C([2H])([2H])[2H])=O)O1)C=C2)NC2=NO
Molecular Weight
336.35
References & Citations
[1]Sheahan TP, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020 Apr 6. pii: eabb5883. |[2]Toots M, et al. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci Transl Med. 2019 Oct 23;11(515). pii: eaax5866.|[3]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
Shipping Conditions
Room Temperature
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
![Rabbit Polyclonal ATG16L1 Antibody [Dylight 755]](https://cdn.genprice.uk/genprice/genprice5.png)
